James W Young

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2410053/publications.pdf

Version: 2024-02-01

135 papers	10,742 citations	41344 49 h-index	31849 101 g-index
136 all docs	136 docs citations	136 times ranked	12673 citing authors

#	Article	IF	Citations
1	Predominant Autoantibody Production by Early Human B Cell Precursors. Science, 2003, 301, 1374-1377.	12.6	1,806
2	Infusions of Donor Leukocytes to Treat Epstein-Barr Virus-Associated Lymphoproliferative Disorders after Allogeneic Bone Marrow Transplantation. New England Journal of Medicine, 1994, 330, 1185-1191.	27.0	1,040
3	Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood, 2012, 119, 2644-2656.	1.4	389
4	Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. Journal of Clinical Investigation, 2005, 115, 2914-2923.	8.2	309
5	Human Dendritic Cells: Potent Antigen-Presenting Cells at the Crossroads of Innate and Adaptive Immunity. Journal of Immunology, 2005, 175, 1373-1381.	0.8	286
6	Dendritic Cells. Advances in Immunology, 1999, 72, 255-324.	2.2	269
7	Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. Journal of Experimental Medicine, 2009, 206, 1423-1434.	8.5	269
8	Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant. Science Translational Medicine, 2018, 10, .	12.4	258
9	Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood, 2009, 114, 3101-3112.	1.4	256
10	Indoleamine 2,3-dioxygenaseâ€“expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood, 2009, 114, 555-563.	1.4	235
11	CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas. Cancer Discovery, 2017, 7, 38-53.	9.4	218
12	T-Cellâ€“Depleted Allogeneic Bone Marrow Transplantation as Postremission Therapy for Acute Myelogenous Leukemia: Freedom From Relapse in the Absence of Graft-Versus-Host Disease. Blood, 1998, 91, 1083-1090.	1.4	217
13	Colonization, Bloodstream Infection, and Mortality Caused by Vancomycin-Resistant Enterococcus Early after Allogeneic Hematopoietic Stem Cell Transplant. Biology of Blood and Marrow Transplantation, 2007, 13, 615-621.	2.0	189
14	Human Liver Dendritic Cells Promote T Cell Hyporesponsiveness. Journal of Immunology, 2009, 182, 1901-1911.	0.8	186
15	Mature Human Langerhans Cells Derived from CD34+ Hematopoietic Progenitors Stimulate Greater Cytolytic T Lymphocyte Activity in the Absence of Bioactive IL-12p70, by Either Single Peptide Presentation or Cross-Priming, Than Do Dermal-Interstitial or Monocyte-Derived Dendritic Cells. Journal of Immunology, 2004, 173, 2780-2791.	0.8	165
16	Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation. Blood, 2012, 120, 4882-4891.	1.4	165
17	Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. Journal of Clinical Investigation, 2020, 130, 733-747.	8.2	161
18	Direct evidence for new T-cell generation by patients after either T-cellâ€“depleted or unmodified allogeneic hematopoietic stem cell transplantations. Blood, 2002, 100, 2235-2242.	1.4	156

#	Article	IF	Citations
19	T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy. Cancer Immunology Research, 2016, 4, 61-71.	3.4	152
20	Availability of Cord Blood Extends Allogeneic Hematopoietic Stem Cell Transplant Access to Racial and Ethnic Minorities. Biology of Blood and Marrow Transplantation, 2010, 16, 1541-1548.	2.0	145
21	Accessory cell requirements for the mixed-leukocyte reaction and polyclonal mitogens, as studied with a new technique for enriching blood dendritic cells. Cellular Immunology, 1988, 111, 167-182.	3.0	144
22	Infection of mature monocyte-derived dendritic cells with human cytomegalovirus inhibits stimulation of T-cell proliferation via the release of soluble CD83. Blood, 2004, 103, 4207-4215.	1.4	139
23	Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. Blood, 2003, 101, 1422-1429.	1.4	119
24	Cord Blood Units with Low CD34+ Cell Viability Have a Low Probability of Engraftment after Double Unit Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 500-508.	2.0	118
25	Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 705-709.	2.0	112
26	Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cells. Blood, 2005, 105, 266-273.	1.4	110
27	Circulating human B cells that express surrogate light chains and edited receptors. Nature Immunology, 2000, 1, 207-213.	14.5	109
28	High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation. Blood, 2015, 125, 199-205.	1.4	109
29	Identification of poor prognostic features among patients requiring mechanical ventilation after hematopoietic stem cell transplantation. Blood, 2001, 98, 3234-3240.	1.4	106
30	T cellâ€“depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin. Blood, 2007, 110, 4552-4559.	1.4	106
31	Signals arising from antigen-presenting cells. Current Opinion in Immunology, 1991, 3, 361-372.	5.5	91
32	The Hematopoietic Development of Dendritic Cells: A Distinct Pathway for Myeloid Differentiation. Stem Cells, 1996, 14, 376-387.	3.2	86
33	Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cellâ€“stimulated T cells yet preserves immunity to recall antigen. Blood, 2011, 118, 5330-5339.	1.4	86
34	Retrovirally Transduced Human Dendritic Cells Express a Normal Phenotype and Potent T-Cell Stimulatory Capacity. Blood, 1997, 90, 2160-2167.	1.4	83
35	T Cellâ€“Depleted Unrelated Donor Stem Cell Transplantation Provides Favorable Disease-Free Survival for Adults with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2011, 17, 1335-1342.	2.0	74
36	Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile. Cancer Immunology Research, 2018, 6, 900-909.	3.4	73

#	Article	IF	Citations
37	Reduced Late Mortality Risk Contributes to Similar Survival after Double-Unit Cord Blood Transplantation Compared with Related and Unrelated Donor Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 1316-1326.	2.0	72
38	Chronic Kidney Disease, Thrombotic Microangiopathy, and Hypertension Following T Cell-Depleted Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 976-984.	2.0	71
39	Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants. Blood, 2006, 108, 2470-2475.	1.4	70
40	Peptide-Loaded Langerhans Cells, Despite Increased IL15 Secretion and T-Cell ActivationIn Vitro, Elicit Antitumor T-Cell Responses Comparable to Peptide-Loaded Monocyte-Derived Dendritic CellsIn Vivo. Clinical Cancer Research, 2011, 17, 1984-1997.	7.0	67
41	Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations. Blood, 2002, 100, 2235-42.	1.4	67
42	Transplantation in Remission Improves the Disease-Free Survival of Patients with Advanced Myelodysplastic Syndromes Treated with Myeloablative T Cell-Depleted Stem Cell Transplants from HLA-Identical Siblings. Biology of Blood and Marrow Transplantation, 2008, 14, 458-468.	2.0	64
43	Distinct Responses of Human Monocyte Subsets to Aspergillus fumigatus Conidia. Journal of Immunology, 2009, 183, 2678-2687.	0.8	63
44	A Novel Reduced-Intensity Conditioning Regimen Induces a High Incidence of Sustained Donor-Derived Neutrophil and Platelet Engraftment after Double-Unit Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 799-803.	2.0	63
45	Retrovirally Transduced Mouse Dendritic Cells Require CD4+ T Cell Help to Elicit Antitumor Immunity: Implications for the Clinical Use of Dendritic Cells. Journal of Immunology, 2000, 164, 1243-1250.	0.8	61
46	Expression of a Functional Eotaxin (CC Chemokine Ligand 11) Receptor CCR3 by Human Dendritic Cells. Journal of Immunology, 2002, 169, 2925-2936.	0.8	58
47	Response to Pneumococcal (PNCRM7) and Haemophilus Influenzae Conjugate Vaccines (HIB) in Pediatric and Adult Recipients of an Allogeneic Hematopoietic Cell Transplantation (alloHCT). Biology of Blood and Marrow Transplantation, 2008, 14, 1022-1030.	2.0	58
48	Direct evidence for new T-cell generation by patients after either T-cellâ€“depleted or unmodified allogeneic hematopoietic stem cell transplantations. Blood, 2002, 100, 2235-2242.	1.4	57
49	Pre-Engraftment Syndrome after Double-Unit Cord Blood Transplantation: A Distinct Syndrome not Associated with Acute Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 2010, 16, 435-440.	2.0	54
50	Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant. Leukemia and Lymphoma, 2017, 58, 1859-1871.	1.3	54
51	CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse. Biology of Blood and Marrow Transplantation, 2015, 21, 2106-2114.	2.0	49
52	Fludarabine-Based Conditioning Secures Engraftment of Second Hematopoietic Stem Cell Allografts (HSCT) in the Treatment of Initial Graft Failure. Biology of Blood and Marrow Transplantation, 2007, 13, 1313-1323.	2.0	48
53	Brincidofovir for Polyomavirus-Associated Nephropathy After Allogeneic Hematopoietic Stem Cell Transplantation. American Journal of Kidney Diseases, 2015, 65, 780-784.	1.9	48
54	A protective Langerhans cellâ€“keratinocyte axis that is dysfunctional in photosensitivity. Science Translational Medicine, 2018, 10, .	12.4	48

#	Article	IF	Citations
55	Dendritic cells have the option to express IDO-mediated suppression or not. Blood, 2005, 105, 2618-2618.	1.4	47
56	NCI First International Workshop on the Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: Report from the Committee on Prevention of Relapse Following Allogeneic Cell Transplantation for Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2010, 16, 1037-1069.	2.0	47
57	Human Langerhans cells use an IL-15R-Î±/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1. Blood, 2012, 119, 5182-5190.	1.4	46
58	Frequent Human Herpesvirus-6 Viremia But Low Incidence of Encephalitis in Double-Unit Cord Blood Recipients Transplanted Without Antithymocyte Globulin. Biology of Blood and Marrow Transplantation, 2014, 20, 787-793.	2.0	43
59	Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant. Leukemia and Lymphoma, 2012, 53, 1124-1129.	1.3	41
60	T Cellâ€“Depleted Stem Cell Transplantation for Adults with High-Risk Acute Lymphoblastic Leukemia: Long-Term Survival for Patients in First Complete Remission with a Decreased Risk of Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2013, 19, 208-213.	2.0	41
61	High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cellâ€“Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous Leukemia. Biology of Blood and Marrow Transplantation, 2015, 21, 1985-1993.	2.0	40
62	Antiâ€“IL6-receptor-alpha (tocilizumab) does not inhibit human monocyte-derived dendritic cell maturation or alloreactive T-cell responses. Blood, 2011, 118, 5340-5343.	1.4	38
63	CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibodyâ€“based therapy. Blood, 2008, 111, 3403-3406.	1.4	37
64	Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial. OncoImmunology, 2018, 7, e1372081.	4.6	37
65	Ex Vivo CD34+â€“Selected T Cellâ€“Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response. Biology of Blood and Marrow Transplantation, 2017, 23, 452-458.	2.0	35
66	Dendritic Cells in Transplantation and Immune-Based Therapies. Biology of Blood and Marrow Transplantation, 2007, 13, 23-32.	2.0	33
67	Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 920-925.	2.0	33
68	Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade. Cancer Immunology Research, 2017, 5, 52-60.	3.4	32
69	Innate Immune Response of Human Plasmacytoid Dendritic Cells to Poxvirus Infection Is Subverted by Vaccinia E3 via Its Z-DNA/RNA Binding Domain. PLoS ONE, 2012, 7, e36823.	2.5	32
70	Robust Vaccine Responses in Adult and Pediatric Cord Blood Transplantation Recipients Treated for Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2015, 21, 2160-2166.	2.0	31
71	New insights into the phenotype of human dendritic cell populations. Clinical and Translational Immunology, 2016, 5, e61.	3.8	29
72	High progression-free survival after intermediate intensity double unit cord blood transplantation in adults. Blood Advances, 2020, 4, 6064-6076.	5.2	29

#	Article	IF	Citations
73	Intravenous Busulfan and Melphalan, Tacrolimus, and Short-Course Methotrexate Followed by Unmodified HLA-Matched Related or Unrelated Hematopoietic Stem Cell Transplantation for the Treatment of Advanced Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2007, 13, 235-244.	2.0	25
74	Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34 + Selected Grafts for Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 67-74.	2.0	24
75	The Sensitization Phase of T-Cell-Mediated Immunity. Annals of the New York Academy of Sciences, 1988, 546, 80-90.	3.8	22
76	Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1079-1087.	2.0	20
77	Ex Vivo T Cell-Depleted Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia in First and Second Remission: Long-Term Disease-Free Survival with a Significantly Reduced Risk of Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2020, 26, 323-332.	2.0	19
78	Dendritic cells: expansion and differentiation with hematopoietic growth factors. Current Opinion in Hematology, 1999, 6, 135.	2.5	19
79	Langerhans-type and monocyte-derived human dendritic cells have different susceptibilities to mRNA electroporation with distinct effects on maturation and activation: implications for immunogenicity in dendritic cell-based immunotherapy. Journal of Translational Medicine, 2013, 11, 166.	4.4	18
80	Progenitor Recruitment and in Vitro Expansion of Immunostimulatory Dendritic Cells from Human CD34+ Bone Marrow Cells by c-kit-Ligand, GM-CSF, and TNFÎ±. Advances in Experimental Medicine and Biology, 1995, 378, 17-20.	1.6	18
81	Dendritic Cells as Immunologic Adjuvants for the Treatment of Cancer. Journal of Clinical Oncology, 2000, 18, 3879-3882.	1.6	17
82	Langerhans Cells Derived from Genetically Modified Human CD34+ Hemopoietic Progenitors Are More Potent Than Peptide-Pulsed Langerhans Cells for Inducing Antigen-Specific CD8+ Cytolytic T Lymphocyte Responses. Journal of Immunology, 2005, 174, 758-766.	0.8	17
83	Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant. Leukemia and Lymphoma, 2021, 62, 3394-3401.	1.3	17
84	The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT. Blood Advances, 2022, 6, 1525-1535.	5.2	17
85	Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy. Transplantation and Cellular Therapy, 2021, 27, 771.e1-771.e10.	1.2	17
86	Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richterâ€™s transformation. Blood Advances, 2021, 5, 2879-2889.	5.2	16
87	Langerhans dendritic cell vaccine bearing mRNA-encoded tumor antigens induces antimyeloma immunity after autotransplant. Blood Advances, 2022, 6, 1547-1558.	5.2	16
88	Hyperfractionated total lymphoid irradiation and cyclophosphamide for preparation of previously transfused patients undergoing HLA-identical marrow transplantation for severe aplastic anemia. International Journal of Radiation Oncology Biology Physics, 1994, 29, 847-854.	0.8	12
89	T Cell Depletion as an Alternative Approach for Patients 55 Years or Older Undergoing Allogeneic Stem Cell Transplantation as Curative Therapy for Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2017, 23, 1685-1694.	2.0	12
90	Racial disparities in access to alternative donor allografts persist inÂthe era of â€œdonors for allâ€• Blood Advances, 2022, 6, 5625-5629.	5.2	12

#	Article	IF	Citations
91	Growth and Differentiation of Human Dendritic Cells from CD34+ Progenitors. Advances in Experimental Medicine and Biology, 1997, 417, 15-19.	1.6	11
92	A prospective study of an alemtuzumab containing reduced-intensity allogeneic stem cell transplant program in patients with poor-risk and advanced lymphoid malignancies. Leukemia and Lymphoma, 2014, 55, 2739-2747.	1.3	9
93	Association between Nondominant Unit Total Nucleated Cell Dose and Engraftment in Myeloablative Double-Unit Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1981-1984.	2.0	9
94	A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies. Biology of Blood and Marrow Transplantation, 2017, 23, 2088-2095.	2.0	9
95	Mononuclear phagocytes as targets for cytolytic T lymphocytes. Journal of Immunological Methods, 1987, 100, 99-106.	1.4	8
96	Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa. Biology of Blood and Marrow Transplantation, 2016, 22, 1449-1454.	2.0	8
97	Phase II Trial of a Chemotherapy-Only Regimen of Busulfan, Melphalan, Fludarabine and R-ATG Followed by Allogeneic T-Cell Depleted (TCD) Hematopoietic Stem Cell Transplants (HSCT) for the Treatment of Myeloid Malignancies.. Blood, 2007, 110, 2991-2991.	1.4	8
98	Langerhans-Type Dendritic Cells Genetically Modified to Express Full-Length Antigen Optimally Stimulate CTLs in a CD4-Dependent Manner. Journal of Immunology, 2006, 176, 2357-2365.	0.8	7
99	Barriers to Clinical Trials Vary According to the Type of Trial and the Institution. Journal of Clinical Oncology, 2007, 25, 1633-1634.	1.6	7
100	Disease-Free Survival After Cord Blood (CB) Transplantation Is Not Different to That After Related or Unrelated Donor Transplantation in Patients with Hematologic Malignancies.. Blood, 2009, 114, 2296-2296.	1.4	6
101	Erythromelalgia precipitated by acral erythema in the setting of thrombocytopenia. Journal of the American Academy of Dermatology, 2003, 48, 973-975.	1.2	5
102	Scalable Expansion of Potent Genetically Modified Human Langerhans Cells in a Closed System for Clinical Applications. Journal of Immunotherapy, 2007, 30, 634-643.	2.4	5
103	Phenotypic and Functional Activation of Hyporesponsive KIRnegNKG2Aneg Human NK-Cell Precursors Requires IL12p70 Provided by Poly(I:C)-Matured Monocyte-Derived Dendritic Cells. Cancer Immunology Research, 2014, 2, 1000-1010.	3.4	5
104	Less Can Be More When Targeting Interleukin-6-Mediated Cytokine Release Syndrome in Coronavirus Disease 2019. , 2020, 2, e0138.		5
105	Poor Graft Function in Recipients of T Cell Depleted (TCD) Allogeneic Hematopoietic Stem Cell Transplants (HSCT) Is Mostly Related to Viral Infections and Anti-Viral Therapy.. Blood, 2012, 120, 3147-3147.	1.4	5
106	Sirolimus (Rapamycin) Induced Proteinuria in a Patient Undergoing Allogeneic Hematopoietic Stem Cell Transplant. Transplantation, 2008, 86, 180-181.	1.0	4
107	Geriatric syndromes in 2-year, progression-free survivors among older recipients of allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 289-292.	2.4	4
108	Low-dose unfractionated heparin prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome after myeloablative adult allogenic stem cell transplant. Bone Marrow Transplantation, 2022, 57, 1095-1100.	2.4	4

#	Article	IF	Citations
109	Fourth complete remission with immunosuppression withdrawal and irinotecan after both autologous and allogeneic transplants for diffuse large B cell lymphoma. Leukemia and Lymphoma, 2009, 50, 2075-2077.	1.3	3
110	Immunogenicity of Haemophilus Influenza and Pneumococcal Vaccines in Related and Unrelated Transplant Recipients.. Blood, 2006, 108, 592-592.	1.4	3
111	Outcomes of adult T-Cell leukemia/lymphoma with allogeneic stem cell transplantation: single-institution experience. Leukemia and Lymphoma, 2021, 62, 2177-2183.	1.3	2
112	Alternative mechanisms that mediate graft-versus-host disease in allogeneic hematopoietic cell transplants. Journal of Clinical Investigation, 2020, 130, 4532-4535.	8.2	2
113	Transfusion Medicine: New Clinical Applications of Cellular Immunotherapy. Hematology American Society of Hematology Education Program, 2000, 2000, 356-375.	2.5	2
114	Vaccine Reponses Following Unmodified or T Cell Depleted Unrelated and Mismatched Related HCT.. Blood, 2004, 104, 2226-2226.	1.4	2
115	Two Chemotherapy-Based Conditioning Regimens Compared To TBI-Based Conditioning Secure Consistent Engraftment Of T-Cell Depleted Allogeneic HSCT, Similarly Low Incidences Of Gvhd and Favorable Rates Of Disease-Free Survival (DFS). Blood, 2013, 122, 546-546.	1.4	2
116	T-Cellâ€“Depleted Allogeneic Bone Marrow Transplantation as Postremission Therapy for Acute Myelogenous Leukemia: Freedom From Relapse in the Absence of Graft-Versus-Host Disease. Blood, 1998, 91, 1083-1090.	1.4	2
117	High Day 28 ST2 Biomarker Levels Predict Severe Day 100 Acute Graft-Versus-Host Disease and Day 180 Transplant-Related Mortality after Double-Unit Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, S278-S279.	2.0	1
118	Langerhans cells: straight from blood to skin?. Blood, 2015, 125, 420-422.	1.4	1
119	Characteristics and Impact of Post-Transplant Interdisciplinary Palliative Care Consultation in Older Allogeneic Hematopoietic Cell Transplant Recipients. Journal of Palliative Medicine, 2020, 23, 1653-1657.	1.1	1
120	Transfusion Medicine: New Clinical Applications of Cellular Immunotherapy. Hematology American Society of Hematology Education Program, 2000, 2000, 356-375.	2.5	1
121	Analysis of 129 Myeloablative Double-Unit Cord Blood Transplantation Recipients Demonstrates an Independent Association Between Non-Dominant Unit TNC Dose and Engraftment Suggesting a Facilitation Effect. Blood, 2014, 124, 2459-2459.	1.4	1
122	Cancer Vaccines: Gene Therapy and Dendritic Cell-Based Vaccines. , 2002, , 319-325.		0
123	Cytomegalovirus Infection of Dendritic Cells. , 0, , 813-828.		0
124	Immunological Aspects of Transplantation. , 0, , 331-348.		0
125	Tregs served sunny-side up. Blood, 2010, 116, 4736-4737.	1.4	0
126	Favorable long-term outcomes of hematopoietic stem cell transplantation for CMML with myeloablative conditioning, anti-thymocyte globulin, and CD34+ selected graft. Bone Marrow Transplantation, 2020, 55, 1632-1634.	2.4	0

#	Article	IF	Citations
127	Combining the disease risk index and hematopoietic cell transplant coâ€morbidity index provides a comprehensive prognostic model for CD34 ⁺ â€selected allogeneic transplantation. Advances in Cell and Gene Therapy, 2021, 4, .	0.9	0
128	Fractionated Infusion of Hematopoietic Progenitor Cells Does Not Improve Neutrophil Recovery or Survival in Allograft Recipients. Transplantation and Cellular Therapy, 2021, 27, 852.e1-852.e9.	1.2	0
129	Results of T Cell Depleted (TCD) Myeloablative Hematopoietic Stem Cell Transplants (HSCT) in Patients with Hematologic Malignancies â‰¥ 55 yrs of Age.. Blood, 2005, 106, 3660-3660.	1.4	0
130	Analysis of 121 Allograft Recipients for the Treatment of Lymphoma: Progressive Disease by Functional and/or CT Imaging Is a Critical Determinant of Survival.. Blood, 2007, 110, 1658-1658.	1.4	0
131	Improved Survival in Patients with Refractory Cytopenias (Low Risk Myelodysplastic Syndrome - MDS) Treated with Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplants (allo TCD-HSCTs),. Blood, 2011, 118, 3831-3831.	1.4	0
132	Human Dendritic Cell Heterogeneity: Opportunities and Challenges for the Control of Immunity. Blood, 2012, 120, SCI-21-SCI-21.	1.4	0
133	Unrelated Donor T-Cell Depleted (TCD) Hematopoietic Stem Cell Transplantation (HSCT) for Patients with Advanced Myelodysplastic Syndromes (MDS): The MSKCC Experience. Blood, 2012, 120, 1996-1996.	1.4	0
134	T-Cell Depleted (TCD) Hematopoietic Stem Cell Transplantation (HCT) For Adult Patients With Acute Myelogenous Leukemia (AML) In First and Second Remission: Long-Term Disease Free Survival(DFS) With a Significantly Reduced Risk Of Graft-Versus-Host Disease(GvHD). Blood, 2013, 122, 3387-3387.	1.4	0
135	Clinical Outcomes of Acute Myeloid Leukemia Patients Bridged to Allogeneic Stem Cell Transplant By Venetoclax Combination Therapy. Blood, 2020, 136, 16-17.	1.4	0